Furthermore, we observed that lower expression levels of YBX3 were associated with improved clinical outcomes for ICB therapy (PDL1 or PD1) in bladder cancer and glioblastomas and consequently longer survival times (Supplementary Figure S1–5B, upper row). Here, YBX3 is linked to urinary bladder carcinoma.